Efficacy and Safety of Oteseconazole in Severe Vulvovaginal Candidiasis Categorized by Candida Species and Previous Genital Tract Infection: A Post Hoc Analysis of a Phase 3 Trial Authors: Xiaoqian Wang, Fengxia Xue, Chunlian Zhang, Ruifang An, Hongjie Ruan, Liancheng Zhu, Liping Zhang, Qinping Liao Published: 2026 ABSTRACT PurposeOteseconazole, a novel selective fungal CYP51 inhibitor, demonstrated superior efficacy over fluconazole for severe vulvovaginal candidiasis (SVVC) in a phase 3 trial. However, whether the efficacy and safety of oteseconazole on SVVC varies by Candida species or previous genital tract infection remains unknown.Patients and MethodsIn this exploratory post hoc analysis of a phase 3 trial (NCT04956419), data were analyzed from patients with SVVC receiving oteseconazole (600 mg on day 1 and 450 mg on day 2) or fluconazole (150 mg on days 1 and 4). The primary outcome was therapeutic cure rate at day 28, assessed in subgroups categorized by Candida species (Candida albicans vs. non-Candida albicans) and previous genital tract infection (yes vs. no).ResultsOf 319 patients categorized by Candida species or previous genital tract infection (oteseconazole, n = 160; fluconazole, n = 159), 249 were in the Candida albicans subgroup and 70 in the non-Candida albicans subgroup. Regarding previous infection, 107 had previous genital tract infection, while 212 had none. At day 28, the therapeutic cure rates were higher with oteseconazole than with fluconazole across subgroups categorized by Candida species (Candida albicans: 76.56% vs 56.20%, propensity score [PS]-weighted odds ratio [OR] 2.59 [95% CI 1.76, 3.81]; non-Candida albicans: 28.13% vs 13.16%, PS-weighted OR 2.78 [95% CI 1.17, 6.64]) and previous genital tract infection (yes: 61.70% vs 45.00%, PS-weighted OR 2.03 [95% CI 1.18, 3.51]); no: 69.03% vs 46.46%, PS-weighted OR 2.59 [95% CI 1.74, 3.85]). Additionally, the incidence of treatment-emergent adverse events was comparable between oteseconazole and fluconazole across all subgroups.ConclusionOteseconazole may offer benefits and is generally well tolerated in patients with SVVC, irrespective of Candida species and previous genital tract infection. However, given the exploratory post hoc nature and the relatively small subgroup sample size, these findings warrant further validation in larger studies. Introduction Vulvovaginal candidiasis (VVC) is the second most prevalent mucosal infectious disorder of the female lower genital tract, occurring most frequently among women of reproductive age (20–40 years old).1 This disease is typically characterized by vulvar pruritus and burning pain, often accompanied by vaginal discomfort and irritation, which may result in dyspareunia and dysuria, thereby exerting a substantial negative impact on quality of life.2 Approximately 70–75% of women experience at least one episode of VVC during their lifetime, with the global prevalence among symptomatic women ranging from 12.1% to 57.3%.2,3 Candida albicans is always the predominant pathogen of VVC, accounting for approximately 70–90% of cases. However, infections attributable to non-Candida albicans species, such as Candida glabrata, Candida tropicalis, and Candida krusei, have shown an increasing prevalence in recent years and are often associated with a higher risk of recurrence.4 Azole antifungals, particularly fluconazole, are the mainstay of treatment for VVC. Nevertheless, both intrinsic and acquired resistance mechanisms to azole agents complicate the management of infections associated with non-Candida albicans species,5,6 further limiting the efficacy of conventional treatments and highlighting the need for species-specific therapeutic evaluation. Clinical data indicate that traditional azole therapy for VVC yields mycological cure rates of over 60% for Candida albicans, while less than 50% for non-Candida albicans species.7 In addition, patients with a history of genital tract infections (eg, bacterial vaginosis, trichomoniasis) often present more complex clinical management challenges. Therapeutic agents used for these infections, particularly antibiotics, can disrupt the vaginal microbiota, thereby predisposing the episode or recurrence of VVC.8 This predisposition often leads to concomitant prophylactic administration of fluconazole, which may, in turn, facilitate antifungal resistance and consequently attenuate the efficacy of subsequent antifungal therapies. These underscore the clinical importance of assessing outcomes according to patients’ prior genital tract infection history. Furthermore, the growing resistance of Candida species to conventional azole antifungals, along with the limited effective therapeutic alternatives, renders the management of VVC challenging, particularly in patients with a history of genital tract infections. Consequently, there is an urgent need to develop novel antifungal strategies for these patient populations. Oteseconazole, also known as VT-1161 or SHR-8008, is a novel oral antifungal agent with a tetrazole moiety and can inhibit fungal CYP51 with high specificity.9 Accumulating clinical evidence indicates that oteseconazole yields superior therapeutic efficacy in severe VVC, acute VVC, and recurrent VVC.10–12 For instance, in patients with severe VVC, a multicenter, randomized, double-blinded, phase 3 trial conducted in China demonstrated that oteseconazole conferred superior efficacy compared with fluconazole, with higher rates of day-28 therapeutic cure (ie, clinical and mycological cure; 66.88% vs 45.91%, P = 0.0002), mycological cure (82.50% vs 59.12%, P < 0.0001) and clinical cure (71.25% vs 55.97%, P = 0.0046).11 Furthermore, oteseconazole was generally tolerated in this patient population. However, the generalizability of these favorable results to specific, clinically challenging subpopulations, such as those with different Candida species or previous genital tract infection, has not yet been fully explored. Based on these, we conducted an exploratory post hoc analysis to evaluate the efficacy and safety of oteseconazole versus fluconazole in patients with severe VVC, categorized by Candida species and previous genital tract infection. Methods Study Design and Patients This exploratory post hoc analysis included data from a multicentre, randomized, double-blinded, phase 3 trial (NCT04956419). The full details of this phase 3 trial have been reported previously.11 In brief, key inclusion criteria were female, 18–75 years of age, with a vulvovaginal signs and symptoms (VSS) score of ≥7 and microscopic confirmed evidence of positive Candida species in vaginal discharge, as assessed by potassium hydroxide (KOH) or Gram staining. Patients with ongoing or a history of recurrent VVC or with concomitant other pathogens-caused vulvovaginitis or pregnancy were excluded. Approval for this phase 3 trial was obtained from the ethics committee of each study site (full list as shown in Supplementary Table 1) and written informed consent was obtained from all patients. The study was conducted in accordance with the Declaration of Helsinki. Treatment Patients were randomly assigned in a 1:1 ratio to receive oral administration of either oteseconazole (600 mg [150 per capsule] on day 1 and 450 mg on day 2) and fluconazole matching placebo (150 mg [50 mg per capsule] on day 1 and 150 mg on day 4), or fluconazole (150 mg on days 1 and 4) and oteseconazole matching placebo (600 mg on day 1 and 450 mg on day 2). Rescue therapy with clotrimazole vaginal tablets (500 mg on days 1 and 4) was permitted at the investigator’s discretion for patients who, one week after the initial dose, showed persistent Candida infection on microscopy accompanied by inadequate symptom relief, symptom exacerbation, or signs of intolerance. Outcomes and Participant Subgroups The primary outcome was therapeutic cure rate at day 28, defined as the proportion of patients achieving both clinical cure (complete resolution of signs and symptoms) and mycological cure (negative Candida culture from vaginal swabs). Secondary outcomes included therapeutic cure rate at day 14, clinical and mycological cure rates at days 14 and 28, the percentage of patients who required rescue antifungal treatment, and the incidence of adverse events (AEs) throughout the study. Outcomes were assessed in subgroups by Candida species (Candida albicans vs. non-Candida albicans) and previous genital tract infection (yes vs. no). Statistical Analysis Efficacy analyses were performed in all randomized patients with positive culture for Candida species at screening. Safety analyses were conducted in all randomized patients who received at least one dose of the study intervention. Baseline patient characteristics and safety data were described using descriptive statistics, with continuous variables expressed as mean (standard deviation [SD]) and categorical variables presented as number (percentage). Data were analyzed in subgroups by Candida species (Candida albicans vs. non-Candida albicans) and previous genital tract infection (yes vs. no). Baseline covariate balance between groups was assessed using the standardized mean difference (SMD), with an absolute SMD > 0.1 considered indicative of imbalance. In the Candida albicans subgroup, age was identified as the imbalanced baseline characteristic; while in the non-Candida albicans subgroup, the imbalanced baseline characteristics were age, body mass index (BMI), age of menarche, and baseline VSS score. Among patients with previous genital tract infection, the imbalanced baseline characteristics were age, BMI, age of menarche, and baseline VSS score. Among patients without such infection, the imbalanced baseline characteristics were age, age of menarche, and baseline VSS score. Propensity scores were calculated using logistic regression, incorporating all imbalanced baseline characteristics. Inverse probability of treatment weighting (IPTW) analysis based on propensity scores (PS) was performed for binary efficacy outcomes using logistic regression, and ANCOVA model adjusting baseline VSS score was used for continuous efficacy outcomes. Odds ratios (ORs) were estimated using weighted logistic regression. The 95% confidence intervals (CIs) were calculated using the normal approximation method. All statistical analyses were performed using SAS software, version 9.4. Results Patients Of 321 patients who were randomized and treated with oteseconazole or fluconazole (safety analysis population), 319 patients had a positive culture for Candida species at screening (efficacy analysis population) in the phase 3 trial. In this post hoc analysis, 249 patients were included in the Candida albicans subgroup (oteseconazole, n = 128; fluconazole, n = 121) and 70 were in the non-Candida albicans subgroup (n = 32 and 38, respectively). Additionally, 107 patients were categorized into the subgroup with previous genital tract infection (oteseconazole, n = 47; fluconazole, n = 60), and 212 patients into the subgroup without previous infection (oteseconazole, n = 113; fluconazole, n = 99). Baseline patient characteristics were generally comparable between the oteseconazole and fluconazole groups across all subgroups categorized by Candida species and previous genital tract infection (Table 1).Table 1Baseline Patient Characteristics, Categorized by Candida Species and Previous Genital Tract Infection Candida Species SubgroupPrevious Genital Tract Infection SubgroupCandida albicansNon-Candida albicansYesNoOteseconazole(n = 128)Fluconazole(n = 121)Oteseconazole(n = 32)Fluconazole(n = 38)Oteseconazole(n = 47)Fluconazole(n = 60)Oteseconazole(n = 113)Fluconazole(n = 99)Age (year), mean (SD)29.6 (8.22)30.8 (7.32)31.3 (6.77)32.3 (7.95)30.7 (8.96)31.9 (6.94)29.6 (7.52)30.8 (7.79)Ethnicity, n (%) Han123 (96.1)114 (94.2)29 (90.6)35 (92.1)45 (95.7)57 (95.0)107 (94.7)92 (92.9) Other5 (3.9)7 (5.8)3 (9.4)3 (7.9)2 (4.3)3 (5.0)6 (5.3)7 (7.1)Weight (kg), mean (SD)56.0 (9.05)55.6 (9.04)58.8 (9.81)55.6 (7.78)55.0 (7.38)55.9 (7.95)57.2 (9.88)55.5 (9.21)BMI (kg/m2), mean (SD)21.1 (3.51)21.4 (3.15)22.3 (3.33)21.9 (3.16)20.8 (2.55)21.4 (2.79)21.6 (3.80)21.6 (3.37)Composite VSS score, mean (SD)8.8 (1.81)8.6 (1.93)8.0 (1.31)7.8 (1.28)8.4 (1.67)8.7 (1.98)8.7 (1.78)8.3 (1.73)Candida species, n (%)* Candida albicans128 (100.0)121 (100.0)0039 (83.0)49 (81.7)89 (78.8)72 (72.7) Candida glabrata0022 (68.8)27 (71.1)6 (12.8)9 (15.0)16 (14.2)18 (18.2) Candida tropicalis005 (15.6)3 (7.9)1 (2.1)04 (3.5)3 (3.0) Candida krusei001 (3.1)2 (5.3)1 (2.1)002 (2.0) Candida spherical002 (6.3)2 (5.3)01 (1.7)2 (1.8)1 (1.0) Candida parapsilosis001 (3.1)2 (5.3)001 (0.9)2 (2.0) Kodamaea ohmeri0001 (2.6)0001 (1.0) Candida dubliniensis001 (3.1)0001 (0.9)0 Saccharomyces cerevisiae0001 (2.6)01 (1.7)00 Candida lusitaniae0001 (2.6)0001 (1.0)Susceptibility testing, n (%)#Oteseconazole Sensitive126 (98.4)119 (98.3)29 (90.6)35 (89.7)45 (95.7)59 (98.3)110 (97.3)95 (95.0) Resistant2 (1.6)2 (1.7)1 (3.1)1 (2.6)1 (2.1)1 (1.7)2 (1.8)2 (2.0) Dose-dependently sensitive00000000 Wild strain001 (3.1)1 (2.6)001 (0.9)1 (1.0) Unknown001 (3.1)2 (5.1)1 (2.1)002 (2.0)Fluconazole Sensitive90 (70.3)89 (73.6)26 (81.3)28 (71.8)31 (66.0)42 (70.0)85 (75.2)75 (75.0) Resistant12 (9.4)12 (9.9)3 (9.4)5 (12.8)10 (21.3)4 (6.7)5 (4.4)13 (13.0) Dose-dependently sensitive26 (20.3)20 (16.5)2 (6.3)5 (12.8)6 (12.8)14 (23.3)22 (19.5)11 (11.0) Wild strain001 (3.1)1 (2.6)001 (0.9)1 (1.0) Unknown00000000Notes: *Based on mycological culture of vaginal secretion. #In both the non-Candida albicans and no previous genital tract infection subgroups, one patient with fluconazole in each subgroup presented with two strains (Candida parapsilosis and Kodamaea ohmeri); therefore, the denominators were adjusted to 39 and 100, respectively.Abbreviations: BMI, body mass index; SD, standard deviation; VSS, vulvovaginal signs and symptoms. Table 1Baseline Patient Characteristics, Categorized by Candida Species and Previous Genital Tract Infection Candida Species SubgroupPrevious Genital Tract Infection SubgroupCandida albicansNon-Candida albicansYesNoOteseconazole(n = 128)Fluconazole(n = 121)Oteseconazole(n = 32)Fluconazole(n = 38)Oteseconazole(n = 47)Fluconazole(n = 60)Oteseconazole(n = 113)Fluconazole(n = 99)Age (year), mean (SD)29.6 (8.22)30.8 (7.32)31.3 (6.77)32.3 (7.95)30.7 (8.96)31.9 (6.94)29.6 (7.52)30.8 (7.79)Ethnicity, n (%) Han123 (96.1)114 (94.2)29 (90.6)35 (92.1)45 (95.7)57 (95.0)107 (94.7)92 (92.9) Other5 (3.9)7 (5.8)3 (9.4)3 (7.9)2 (4.3)3 (5.0)6 (5.3)7 (7.1)Weight (kg), mean (SD)56.0 (9.05)55.6 (9.04)58.8 (9.81)55.6 (7.78)55.0 (7.38)55.9 (7.95)57.2 (9.88)55.5 (9.21)BMI (kg/m2), mean (SD)21.1 (3.51)21.4 (3.15)22.3 (3.33)21.9 (3.16)20.8 (2.55)21.4 (2.79)21.6 (3.80)21.6 (3.37)Composite VSS score, mean (SD)8.8 (1.81)8.6 (1.93)8.0 (1.31)7.8 (1.28)8.4 (1.67)8.7 (1.98)8.7 (1.78)8.3 (1.73)Candida species, n (%)* Candida albicans128 (100.0)121 (100.0)0039 (83.0)49 (81.7)89 (78.8)72 (72.7) Candida glabrata0022 (68.8)27 (71.1)6 (12.8)9 (15.0)16 (14.2)18 (18.2) Candida tropicalis005 (15.6)3 (7.9)1 (2.1)04 (3.5)3 (3.0) Candida krusei001 (3.1)2 (5.3)1 (2.1)002 (2.0) Candida spherical002 (6.3)2 (5.3)01 (1.7)2 (1.8)1 (1.0) Candida parapsilosis001 (3.1)2 (5.3)001 (0.9)2 (2.0) Kodamaea ohmeri0001 (2.6)0001 (1.0) Candida dubliniensis001 (3.1)0001 (0.9)0 Saccharomyces cerevisiae0001 (2.6)01 (1.7)00 Candida lusitaniae0001 (2.6)0001 (1.0)Susceptibility testing, n (%)#Oteseconazole Sensitive126 (98.4)119 (98.3)29 (90.6)35 (89.7)45 (95.7)59 (98.3)110 (97.3)95 (95.0) Resistant2 (1.6)2 (1.7)1 (3.1)1 (2.6)1 (2.1)1 (1.7)2 (1.8)2 (2.0) Dose-dependently sensitive00000000 Wild strain001 (3.1)1 (2.6)001 (0.9)1 (1.0) Unknown001 (3.1)2 (5.1)1 (2.1)002 (2.0)Fluconazole Sensitive90 (70.3)89 (73.6)26 (81.3)28 (71.8)31 (66.0)42 (70.0)85 (75.2)75 (75.0) Resistant12 (9.4)12 (9.9)3 (9.4)5 (12.8)10 (21.3)4 (6.7)5 (4.4)13 (13.0) Dose-dependently sensitive26 (20.3)20 (16.5)2 (6.3)5 (12.8)6 (12.8)14 (23.3)22 (19.5)11 (11.0) Wild strain001 (3.1)1 (2.6)001 (0.9)1 (1.0) Unknown00000000Notes: *Based on mycological culture of vaginal secretion. #In both the non-Candida albicans and no previous genital tract infection subgroups, one patient with fluconazole in each subgroup presented with two strains (Candida parapsilosis and Kodamaea ohmeri); therefore, the denominators were adjusted to 39 and 100, respectively.Abbreviations: BMI, body mass index; SD, standard deviation; VSS, vulvovaginal signs and symptoms. Baseline Patient Characteristics, Categorized by Candida Species and Previous Genital Tract Infection Notes: *Based on mycological culture of vaginal secretion. #In both the non-Candida albicans and no previous genital tract infection subgroups, one patient with fluconazole in each subgroup presented with two strains (Candida parapsilosis and Kodamaea ohmeri); therefore, the denominators were adjusted to 39 and 100, respectively. Abbreviations: BMI, body mass index; SD, standard deviation; VSS, vulvovaginal signs and symptoms. Efficacy Outcomes Candida Species Subgroup At day 28, a markedly higher proportion of patients receiving oteseconazole achieved a therapeutic cure compared with those treated with fluconazole in both the Candida albicans subgroup (76.56% vs 56.20%, PS weighted OR 2.59 [95% CI 1.76, 3.81]) and the non-Candida albicans subgroup (28.13% vs 13.16%, PS weighted OR 2.78 [95% CI 1.17, 6.64]), with no between-group interaction observed (Pinteraction = 0.9833; Figure 1A). Furthermore, oteseconazole was associated with higher clinical and mycological cure rates compared with fluconazole across both Candida species subgroups (clinical cure: 78.13% vs 61.98% for Candida albicans, and 43.75% vs 36.84% for non-Candida albicans; mycological cure: 92.19% vs 71.07% and 43.75% vs 21.05%, respectively; Figure 1A). Figure 1Forest plot for therapeutic cure, clinical cure, and mycological cure with oteseconazole versus fluconazole at day 28 (A) and day 14 (B) across subgroups categorized by Candida species.The image A showing a forest plot titled “At day 28”. A table lists cure type and cure rate (cure number slash subgroup number) for Oteseconazole and Fluconazole, plus “PS weighted OR (95 percent CI)” and “P value for interaction”. The horizontal axis is unlabeled and ranges from 0 to 9 in increments of 1, with text “Favor Fluconazole” on the left and “Favor Oteseconazole” on the right; a vertical reference line is at 1. Therapeutic cure: Candida albicans 76.56 (98 slash 128) vs 56.20 (68 slash 121), PS weighted OR 2.59 (1.76, 3.81); Non-Candida albicans 28.13 (9 slash 32) vs 13.16 (5 slash 38), OR 2.78 (1.17, 6.64). P value for interaction 0.9833. Clinical cure: Candida albicans 78.13 (100 slash 128) vs 61.98 (75 slash 121), OR 2.19 (1.47, 3.25); Non-Candida albicans 43.75 (14 slash 32) vs 36.84 (14 slash 38), OR 1.26 (0.64, 2.47). P value for interaction 0.3808. Mycological cure: Candida albicans 92.19 (118 slash 128) vs 71.07 (86 slash 121), OR 5.12 (2.98, 8.83); Non-Candida albicans 43.75 (14 slash 32) vs 21.05 (8 slash 38), OR 3.41 (1.61, 7.21). P value for interaction 0.4491. The image B showing a forest plot titled “At day 14” with the same columns and the same horizontal axis (unlabeled, 0 to 6 by 1; reference line at 1; “Favor Fluconazole” left and “Favor Oteseconazole” right). Therapeutic cure: Candida albicans 60.94 (78 slash 128) vs 45.45 (55 slash 121), OR 1.90 (1.33, 2.71); Non-Candida albicans 18.75 (6 slash 32) vs 15.79 (6 slash 38), OR 1.24 (0.53, 2.89). P value for interaction 0.5402. Clinical cure: Candida albicans 63.28 (81 slash 128) vs 53.72 (65 slash 121), OR 1.48 (1.04, 2.13); Non-Candida albicans 31.25 (10 slash 32) vs 39.47 (15 slash 38), OR 0.66 (0.33, 1.33). P value for interaction 0.1830. Mycological cure: Candida albicans 92.19 (118 slash 128) vs 79.34 (96 slash 121), OR 3.18 (1.82, 5.54); Non-Candida albicans 40.63 (13 slash 32) vs 26.32 (10 slash 38), OR 1.90 (0.93, 3.87). P value for interaction 0.4682.Two forest plots comparing cure outcomes for oteseconazole versus fluconazole by Candida subgroup.Abbreviations: PS, propensity scores; OR, odds ratio; CI, confidence interval. Forest plot for therapeutic cure, clinical cure, and mycological cure with oteseconazole versus fluconazole at day 28 (A) and day 14 (B) across subgroups categorized by Candida species. At day 14, an improved trend was also observed with oteseconazole than with fluconazole across both Candida species subgroups, as evidenced by higher proportions of patients achieving therapeutic cure (60.94% vs 45.45% for Candida albicans, and 18.75% vs 15.79% for non-Candida albicans), clinical cure (63.28% vs 53.72% and 31.25% vs 39.47%, respectively), and mycological cure (92.19% vs 79.34% and 40.63% vs 26.32%, respectively; Figure 1B). Patients treated with oteseconazole exhibited a greater mean reduction in composite VSS scores from baseline to day 28 compared with those receiving fluconazole, being consistent for both Candida albicans subgroup (−8.6 [1.93] for oteseconazole vs −7.6 [2.59] for fluconazole) and non-Candida albicans subgroup (−7.0 [1.64] vs −6.6 [2.18]; Figure 2). Additionally, in the Candida albicans subgroup, only 2.34% of patients receiving oteseconazole required antifungal rescue therapy, compared with 12.40% in the fluconazole group, while the corresponding proportions were respective 9.38% and 21.05% in the non-Candida albicans subgroup. Figure 2Mean change from baseline in composite VSS score over 28 days across subgroups categorized by Candida species.A line graph with legend entries: Candida albicans dash Fluconazole, Candida albicans dash Oteseconazole, Non-Candida albicans dash Fluconazole, Non- Candida albicans dash Oteseconazole. The horizontal axis label is Visits (Day) with values Baseline, 14, 28. The horizontal axis unit is day. The vertical axis label is Mean Change from Baseline in Composite VSS score. The vertical axis unit is composite VSS score. The vertical axis range shown is 0 to negative 8 with tick labels 0, negative 2, negative 4, negative 6, negative 8. Candida albicans dash Fluconazole: (Baseline, 0), (14, negative 7.8), (28, negative 7.6). Candida albicans dash Oteseconazole: (Baseline, 0), (14, negative 8.2), (28, negative 8.6). Non-Candida albicans dash Fluconazole: (Baseline, 0), (14, negative 6.3), (28, negative 6.6). Non-Candida albicans dash Oteseconazole: (Baseline, 0), (14, negative 6.4), (28, negative 7.0).A line graph showing mean change from baseline in composite VSS score by Candida species and treatment.Abbreviation: VSS, vulvovaginal signs and symptoms. Mean change from baseline in composite VSS score over 28 days across subgroups categorized by Candida species. Previous Genital Tract Infection Subgroup At day 28, oteseconazole demonstrated a higher therapeutic cure rate than fluconazole among patients with previous genital tract infection (61.70% vs 45.00%, PS weighted OR 2.03 [95% CI 1.18, 3.51]). Similarly, among patients without previous genital tract infection, the therapeutic cure rate was 69.03% with oteseconazole compared with 46.46% with fluconazole (PS weighted OR 2.59 [95% CI 1.74, 3.85]; P = 0.5877 for interaction; Figure 3A). Additionally, a higher proportion of patients, irrespective of previous genital tract infection, achieved clinical and mycological cure with oteseconazole compared with fluconazole (clinical cure: 65.96% vs 53.33% for patients with previous genital tract infection, and 73.45% vs 57.58% for those without previous infections; mycological cure: 76.60% vs 61.67% and 84.96% vs 57.58%, respectively; Figure 3A). Figure 3Forest plot for therapeutic cure, clinical cure, and mycological cure with oteseconazole versus fluconazole at day 28 (A) and day 14 (B) across subgroups categorized by previous genital tract infection.The image A showing a forest plot titled “At day 28” comparing oteseconazole versus fluconazole by previous genital tract infections. The x-axis label is “PS weighted OR (95 percent CI)” with tick values 0, 1, 2, 3, 4, 5, 6, 7 (unit not shown). A vertical reference line is at 1. Left text indicates “Favor Fluconazole” and right text indicates “Favor Oteseconazole.” Therapeutic cure: with previous genital tract infections, cure rate 61.70 (29/47) vs 45.00 (27/60), PS weighted OR 2.03 (1.18, 3.51); without previous genital tract infections, 69.03 (78/113) vs 46.46 (46/99), OR 2.59 (1.74, 3.85); P value for interaction 0.5877. Clinical cure: with previous genital tract infections, 65.96 (31/47) vs 53.33 (32/60), OR 1.56 (0.90, 2.69); without previous genital tract infections, 73.45 (83/113) vs 57.58 (57/99), OR 2.10 (1.40, 3.16); P value for interaction 0.7118. Mycological cure: with previous genital tract infections, 76.60 (36/47) vs 61.67 (37/60), OR 2.29 (1.27, 4.13); without previous genital tract infections, 84.96 (96/113) vs 57.58 (57/99), OR 4.18 (2.62, 6.67); P value for interaction 0.1913. The image B showing a forest plot titled “At day 14” with the same x-axis label “PS weighted OR (95 percent CI)” and tick values 0 to 4 (unit not shown) and the same favor labels with a reference line at 1. Therapeutic cure: with previous genital tract infections, cure rate 51.06 (24/47) vs 31.67 (19/60), OR 2.26 (1.29, 3.95); without previous genital tract infections, 53.10 (60/113) vs 42.42 (42/99), OR 1.54 (1.05, 2.27); P value for interaction 0.4345. Clinical cure: with previous genital tract infections, 51.06 (24/47) vs 41.67 (25/60), OR 1.46 (0.85, 2.50); without previous genital tract infections, 59.29 (67/113) vs 55.56 (55/99), OR 1.18 (0.80, 1.73); P value for interaction 0.6382. Mycological cure: with previous genital tract infections, 78.72 (37/47) vs 66.67 (40/60), OR 1.87 (1.01, 3.44); without previous genital tract infections, 83.19 (94/113) vs 66.67 (66/99), OR 2.28 (1.45, 3.61); P value for interaction 0.6023.Two forest plots comparing cure outcomes for oteseconazole versus fluconazole by infection history.Abbreviations: PS, propensity scores; OR, odds ratio; CI, confidence interval. Forest plot for therapeutic cure, clinical cure, and mycological cure with oteseconazole versus fluconazole at day 28 (A) and day 14 (B) across subgroups categorized by previous genital tract infection. At day 14, the therapeutic cure rate for oteseconazole was 51.06% as compared with 31.67% for fluconazole in patients with previous genital tract infection; and in patients without previous genital tract infection, the corresponding rates were 53.10% versus 42.42% (Figure 3B). Improved clinical and mycological cure rates with oteseconazole, compared with fluconazole, were consistently observed across subgroups categorized by previous genital tract infection (with infections: 51.06% vs 41.67% for clinical cure, and 78.72% vs 66.67% for mycological cure; without infections: 59.29% vs 55.56% and 83.19% vs 66.67%, respectively). In terms of composite VSS score, the mean (SD) changes from baseline to day 28 for patients with and without previous genital tract infection were −7.9 (1.90) and-8.4 (1.98) for oteseconazole vs. −7.5 (2.82) and −7.3 (2.34) for fluconazole (Figure 4). Additionally, treatment with oteseconazole was associated with a reduced need for antifungal rescue therapy compared with fluconazole across subgroups categorized by previous genital tract infection (with infections: 8.51% vs. 15.00%; and without infections: 1.77% vs. 14.14%). Figure 4Mean change from baseline in composite VSS score over 28 days across subgroups categorized by previous genital tract infection.A line graph with legend entries: With previous genital tract infection-Fluconazole; With previous genital tract infection-Oteseconazole; Without previous genital tract infection-Fluconazole; Without previous genital tract infection-Oteseconazole. Horizontal axis label: Visits (Day). Horizontal axis categories: Baseline, 14, 28. Vertical axis label: Mean Change from Baseline in Composite VSS score. Vertical axis range shown from 0 to negative 8. Data points by series, listed from Baseline to 28. With previous genital tract infection-Fluconazole: (Baseline, 0), (14, negative 7.4), (28, negative 7.5). With previous genital tract infection-Oteseconazole: (Baseline, 0), (14, negative 7.3), (28, negative 7.9). Without previous genital tract infection-Fluconazole: (Baseline, 0), (14, negative 7.4), (28, negative 7.3). Without previous genital tract infection-Oteseconazole: (Baseline, 0), (14, negative 8.0), (28, negative 8.4).A line graph showing mean change from baseline in composite VSS score by visit day and infection history.Abbreviation: VSS, vulvovaginal signs and symptoms. Mean change from baseline in composite VSS score over 28 days across subgroups categorized by previous genital tract infection. Safety A summary of treatment-emergent AEs (TEAEs) among subgroups categorized by Candida species and previous genital tract infection is presented in Table 2. In the Candida albicans subgroup, 62 (48.8%) patients in the oteseconazole group and 53 (43.8%) in the fluconazole group reported at least one TEAE. In the non-albicans subgroup, TEAEs were reported in 20 (62.5%) patients receiving oteseconazole and 16 (42.1%) receiving fluconazole. Across the previous genital tract infection subgroups, TEAEs were reported in 28 patients (59.6%) with previous genital tract infection receiving oteseconazole and 22 (36.7%) receiving fluconazole, while in 54 (47.8%) and 47 (46.5%) patients without previous genital tract infection, respectively.Table 2Summary of Treatment-Emergent Adverse Events, Categorized by Candida Species and Previous Genital Tract InfectionCandida Species Subgroup*Previous Genital Tract Infection SubgroupCandida albicansNon-Candida albicansYesNoOteseconazole(n = 127)Fluconazole(n = 121)Oteseconazole(n = 32)Fluconazole(n = 38)Oteseconazole(n = 47)Fluconazole(n = 60)Oteseconazole(n = 113)Fluconazole(n = 101)Any TEAEs, n (%)62 (48.8)53 (43.8)20 (62.5)16 (42.1)28 (59.6)22 (36.7)54 (47.8)47 (46.5)Treatment-related AEs, n (%)27 (21.3)24 (19.8)8 (25.0)8 (21.1)11 (23.4)9 (15.0)24 (21.2)23 (22.8)Any serious TEAEs, n (%)01 (0.8)0001 (1.7)00TEAE leading to death, n (%)00000000TEAEs leading to treatment discontinuation, n (%)00000000The most common TEAEs#, n (%)Urinary tract infection9 (7.1)5 (4.1)4 (12.5)2 (5.3)5 (10.6)4 (6.7)8 (7.1)3 (3.0)Bacterial vulvovaginitis6 (4.7)11 (9.1)1 (3.1)1 (2.6)4 (8.5)4 (6.7)3 (2.7)8 (7.9)Bacterial vaginosis1 (0.8)7 (5.8)1 (3.1)3 (7.9)02 (3.3)2 (1.8)8 (7.9)Nausea5 (3.9)5 (4.1)003 (6.4)3 (5.0)2 (1.8)2 (2.0)Upper respiratory tract infection3 (2.4)2 (1.7)2 (6.3)2 (5.3)2 (4.3)03 (2.7)4 (4.0)Dizziness6 (4.7)3 (2.5)004 (8.5)1 (1.7)2 (1.8)2 (2.0)Headache5 (3.9)1 (0.8)1 (3.1)01 (2.1)05 (4.4)1 (1.0)Abdominal discomfort1 (0.8)03 (9.4)1 (2.6)1 (2.1)03 (2.7)1 (1.0)Diarrhoea1 (0.8)2 (1.7)2 (6.3)02 (4.3)01 (0.9)2 (2.0)White blood cell count decreased1 (0.8)002 (5.3)001 (0.9)2 (2.0)Anemia04 (3.3)1 (3.1)0001 (0.9)4 (4.0)Blood creatine phosphokinase increased3 (2.4)2 (1.7)002 (4.3)2 (3.3)1 (0.9)0Blood uric acid increased2 (1.6)3 (2.5)002 (4.3)1 (1.7)02 (2.0)Abdominal pain2 (1.6)1 (0.8)1 (3.1)02 (4.3)01 (0.9)1 (1.0)Mycoplasma infection1 (0.8)1 (0.8)1 (3.1)02 (4.3)1 (1.7)00Notes: *In Candida species subgroup, three patients had negative culture for Candida species, and one did not receive the study treatment; therefore, a total of 318 patients rather than 321 were included in the safety analysis. #TEAEs occurring in > 4% of patients in any group are presented, in both Candida species subgroup and previous genital tract infections subgroup.Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse events. Table 2Summary of Treatment-Emergent Adverse Events, Categorized by Candida Species and Previous Genital Tract InfectionCandida Species Subgroup*Previous Genital Tract Infection SubgroupCandida albicansNon-Candida albicansYesNoOteseconazole(n = 127)Fluconazole(n = 121)Oteseconazole(n = 32)Fluconazole(n = 38)Oteseconazole(n = 47)Fluconazole(n = 60)Oteseconazole(n = 113)Fluconazole(n = 101)Any TEAEs, n (%)62 (48.8)53 (43.8)20 (62.5)16 (42.1)28 (59.6)22 (36.7)54 (47.8)47 (46.5)Treatment-related AEs, n (%)27 (21.3)24 (19.8)8 (25.0)8 (21.1)11 (23.4)9 (15.0)24 (21.2)23 (22.8)Any serious TEAEs, n (%)01 (0.8)0001 (1.7)00TEAE leading to death, n (%)00000000TEAEs leading to treatment discontinuation, n (%)00000000The most common TEAEs#, n (%)Urinary tract infection9 (7.1)5 (4.1)4 (12.5)2 (5.3)5 (10.6)4 (6.7)8 (7.1)3 (3.0)Bacterial vulvovaginitis6 (4.7)11 (9.1)1 (3.1)1 (2.6)4 (8.5)4 (6.7)3 (2.7)8 (7.9)Bacterial vaginosis1 (0.8)7 (5.8)1 (3.1)3 (7.9)02 (3.3)2 (1.8)8 (7.9)Nausea5 (3.9)5 (4.1)003 (6.4)3 (5.0)2 (1.8)2 (2.0)Upper respiratory tract infection3 (2.4)2 (1.7)2 (6.3)2 (5.3)2 (4.3)03 (2.7)4 (4.0)Dizziness6 (4.7)3 (2.5)004 (8.5)1 (1.7)2 (1.8)2 (2.0)Headache5 (3.9)1 (0.8)1 (3.1)01 (2.1)05 (4.4)1 (1.0)Abdominal discomfort1 (0.8)03 (9.4)1 (2.6)1 (2.1)03 (2.7)1 (1.0)Diarrhoea1 (0.8)2 (1.7)2 (6.3)02 (4.3)01 (0.9)2 (2.0)White blood cell count decreased1 (0.8)002 (5.3)001 (0.9)2 (2.0)Anemia04 (3.3)1 (3.1)0001 (0.9)4 (4.0)Blood creatine phosphokinase increased3 (2.4)2 (1.7)002 (4.3)2 (3.3)1 (0.9)0Blood uric acid increased2 (1.6)3 (2.5)002 (4.3)1 (1.7)02 (2.0)Abdominal pain2 (1.6)1 (0.8)1 (3.1)02 (4.3)01 (0.9)1 (1.0)Mycoplasma infection1 (0.8)1 (0.8)1 (3.1)02 (4.3)1 (1.7)00Notes: *In Candida species subgroup, three patients had negative culture for Candida species, and one did not receive the study treatment; therefore, a total of 318 patients rather than 321 were included in the safety analysis. #TEAEs occurring in > 4% of patients in any group are presented, in both Candida species subgroup and previous genital tract infections subgroup.Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse events. Summary of Treatment-Emergent Adverse Events, Categorized by Candida Species and Previous Genital Tract Infection Notes: *In Candida species subgroup, three patients had negative culture for Candida species, and one did not receive the study treatment; therefore, a total of 318 patients rather than 321 were included in the safety analysis. #TEAEs occurring in > 4% of patients in any group are presented, in both Candida species subgroup and previous genital tract infections subgroup. Abbreviations: AE, adverse event; TEAE, treatment-emergent adverse events. Urinary tract infection was the most common TEAE in the oteseconazole group, consistent across subgroups categorized by Candida species (7.1% and 12.5%, respectively) and previous genital tract infection (10.6% and 7.1%, respectively; Table 2). In contrast, in the fluconazole group, bacterial vulvovaginitis or bacterial vaginosis was comparatively more common across the respective subgroups. No serious TEAE occurred in the oteseconazole group. In the fluconazole group, one patient with Candida albicans infection and a history of genital tract infection experienced a serious TEAE (threatened abortion), which was considered unrelated to the treatment. No TEAE resulted in treatment discontinuation or death in any subgroup. Discussion Severe VVC typically represents complicated VVC and are often associated with suboptimal treatment outcomes, especially in patients with previous genital tract infection or those infected by non-Candida albicans species.2,13 Although substantial efficacy of oteseconazole for patients with severe VVC has been established in a phase 3 trial, the impact of Candida species and previous genital tract infection on treatment outcomes remains a key concern. This post hoc analysis, based on data from this phase 3 trial, provided preliminary evidence that oteseconazole may be associated with improved efficacy and safety compared with fluconazole across subgroups categorized by Candida species and previous genital tract infection, potentially supporting the clinical applicability of oteseconazole in more challenging patient populations. This post hoc analysis showed that oteseconazole was associated with higher therapeutic, clinical, and mycological cure rates compared with fluconazole in severe VVC, irrespective of the Candida species involved. Although patients with non-Candida albicans infections exhibited numerically lower treatment outcomes compared with those with Candida albicans infections, a consistent trend favoring oteseconazole over fluconazole was observed. Non-Candida albicans species, particularly Candida glabrata, are typically less susceptible to traditional azole antifungals due to intrinsic or acquired resistance.14 The dominant mechanisms for resistance involve alterations in the synthesis of sterols to replace ergosterol and efflux-gene overexpression.15,16 The consistent efficacy of oteseconazole across Candida species in this post hoc analysis may reflect its potential activity in settings with limited response to conventional azoles; however, these findings are based solely on clinical outcomes and lack the strain-level drug resistance data. Further studies supplementing the strain-level drug resistance data are warranted to clarify the specific mechanism of oteseconazole’s efficacy advantage over fluconazole, which would help to further define the applicable population of oteseconazole at the microbiological level. Previous studies have shown that VVC is associated with previous genital tract infection.17 Administration of intravaginal agents and antibiotics for genital tract infection management may inevitably alter vaginal pH, disturb the ecological balance of the vaginal cavity, and impair the vaginal defense mechanism, often in turn contributing to treatment resistance or VVC recurrence.2 Therefore, the efficacy associated with oteseconazole in patients with previous genital tract infection deserves considerable attention. In this analysis, the beneficial effects of oteseconazole vs fluconazole were similar for patients with and without previous genital tract infection, suggesting the potential applicability of oteseconazole in clinically challenging settings. The observed benefit of oteseconazole in this subgroup also may indicate its potential role in overcoming the vulnerability associated with prior infections. Additionally, compared with fluconazole, oteseconazole was associated with a lower requirement for rescue antifungal therapy across subgroups categorized by Candida species and previous genital tract infection, an effect potentially explained by its prolonged half-life (138 days vs 30 hours) and durable therapeutic effect.9,18 Across all patient subgroups, the incidence of TEAEs in the oteseconazole group was comparable to that in the fluconazole group, consistent with that reported in the overall population.11 This finding indicated that oteseconazole did not appear to increase the overall risk of AEs, even among patients with non-Candida albicans infections or with prior genital tract infection. Oteseconazole was well tolerated, with all AEs being of mild to moderate severity and no treatment-related serious events, events leading to discontinuations, or deaths reported, which further reinforce its potential as a safe therapeutic strategy across Candida species and previous genital tract infection subgroups. One limitation of the present analysis lay in its exploratory post hoc design, with these subgroup analyses not prespecified. In addition, the relatively small sample size, particularly in subgroup with non-Candida albicans infections or previous genital tract infections, may limit statistical power and the generalizability of the findings. The results of this study therefore should be interpreted with caution. Further studies targeting these patient populations are warranted to validate our current findings. Furthermore, the vast majority of patients in this post hoc analysis were of Han Chinese ethnicity. Inclusion of patients from more diverse racial and ethnic backgrounds in future studies will provide valuable insights into the therapeutic efficacy of oteseconazole among patients with severe VVC across different populations. Notwithstanding these limitations, this study is the first to specifically evaluate the impact of Candida species and previous genital tract infection on the efficacy and safety of oteseconazole, and the results suggested the promise of oteseconazole as an emerging oral antifungal with consistent efficacy across Candida species and previous infection backgrounds in severe VVC. Conclusions In this exploratory post-hoc analysis, oteseconazole exhibited potential superiority over fluconazole across all patient subgroups, irrespective of Candida species or previous genital tract infection, with a manageable safety profile. However, given the exploratory post hoc nature of this analysis, these findings should be interpreted with caution. Additional prospective clinical studies are warranted to confirm these findings and to provide a rigorous evidence base for guiding clinical decision-making in severe VVC.